Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory
Release time:
2020-07-31
News from this newspaper 2# March 28 , the 10 meeting of the ninth board of directors of the group company deliberated and passed the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman". On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation.
Beihui Biology was formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through cooperation with Yale University, we have obtained patent authorization and commercial development license for the new anticancer chemical drug troxacitabine (trokacitabine )(the national clinical approval for the new drug has been obtained in 2016 ), the anti-hepatitis B chemical drug clevudine (Clevudine ).
Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biological Holding Company, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly established by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has basically completed the production workshops of percolation, tincture, solid preparation, liquid preparation and other dosage forms, at present, it has entered the GMP certification stage. Guanghui Pharmaceutical has 77 drug approvals mainly for proprietary Chinese medicine preparations. Its main products include Huoxiang Zhengqi Water, Shidishui, Chen Xianglu Bailu Tablets, Compound Pearl Jiedu Oral Liquid, Yigan Mingmu Oral Liquid, etc. Among them, Yigan Mingmu Oral Liquid and Pearl Jiedu Oral Liquid are exclusive products.
According to the cooperation agreement, when the agreed preconditions are met, Jianfeng Pharmaceutical plans to increase the capital of Beihui Biology in four phases. After the agreement comes into effect, it will make the first phase of investment and will contribute ,000 yuan to increase the capital of Beihui Biology in 2,000 shares (accounting for 20% of shares); the second phase contributed ,8600 yuan to increase ,2000 shares of Beihui Biology, and at the same time contributed ,3010 yuan to transfer ,700 shares of Beihui Biology. In the third and fourth phases, the capital increase was ,1400 shares respectively. The capital increase price was determined through negotiation based on the evaluation value of Beihui Biology at that time. If the capital increase and equity transfer are all completed, Peak Pharmaceuticals will hold Beihui Bio 7500 shares (accounting for 50.68% of the equity, the calculation of the equity ratio does not take into account the introduction of other investors). The next few phases of investment will be implemented in stages according to the investment prerequisites agreed in the agreement, the progress of product development, the operation of the target company and other factors.
This cooperation is based on the company's strategic policy of "cooperating and innovating to strengthen the main business, standardizing science and seeking development". It is the specific implementation of expanding and strengthening the pharmaceutical business, which will help to further enhance the new drug research and development capability of Jianfeng Pharmaceutical and further expand the scale of the company's pharmaceutical business. (Zhou Hengbin)
More information
The company's vocational skill level independently identifies two new occupations
A few days ago, after the examination and approval of the Jinhua Municipal Bureau of Human Resources and Social Security, and reported to the Provincial Department of Human Resources and Social Security for examination and filing, Jianfeng Group's independent identification level of vocational skills was based on last year. Two new occupations (types of work) are chemical inspectors and organic synthesis workers.
2022
05-20
On May 12, Cai Xiaochun, deputy secretary of the Party group of Zhejiang Federation of industry and commerce, and his party visited Jianfeng group for investigation, visited Jinxi factory area of Jianfeng pharmaceutical factory and Jinxi internationalization project site, and had a discussion with Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company.
2022
05-20
On the afternoon of April 6, Jiang Xiaomeng, chairman of the group company, was invited to participate in the Jinhua News Client Financial Media Interview column "Night Talk of the Two Sessions", as a representative of the Jinhua Municipal People's Congress, to talk about suggestions for the future development of Jinhua enterprises. As the chairman of the Jinhua City Federation of Industry and Commerce, Jiang Xiaomeng has a personal experience of various problems encountered in the development of Jinhua enterprises. After careful investigation and full preparation, he put forward two proposals on strengthening the empowerment and allocation of production factors and further enhancing the market competitiveness of enterprises in our city and further promoting the compliance construction of private enterprises in our city and reducing the risk of enterprise operation. In the "two sessions night talk" interview, he put forward his own views on these two topics.
2022
04-12
Group Companies Commend 2021 Advanced
On the morning of January 26, the group company held the 2021 annual summary commendation meeting to review the work of the previous year, make arrangements for the work of 2022, sign the 2022 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2021 advanced collectives and individuals.
2022
02-08
Group Company Convenes Workers' Representative and Trade Union Member Representative Conference
The group company held a representative meeting of staff representatives and trade union members, elected members of the eighth trade union committee and members of various special committees, and Shi Fu was elected chairman of the eighth trade union of the group trade union.
2022
02-08
The group company held an annual safety and environmental protection work conference to comprehensively summarize and review the safety and environmental protection work in 2021, make arrangements for the safety and environmental protection work in 2022, and sign the safety and environmental protection work responsibility system.
2022
02-08
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page